JP Morgan Initiates Coverage On Savara with Overweight Rating, Announces Price Target of $12
JP Morgan analyst Caroline Pocher initiates coverage on Savara (NASDAQ:SVRA) with a Overweight rating and announces Price Target of $12.
Stocks · News reference
Savara Announces Acceptance Of Oral Presentation, Two Poster Presentations From Phase 3 IMPALA-2 Clinical Studies At ERS Congress
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led gainers with a 16.3% jump on strong results.
Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041
MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectivelyData Presented at ATS Showed